Antiproteases in the treatment of acute pancreatitis

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 518-525

  Kitagawa, Motoji ^a   Hayakawa, Tetsuo ^b  

^a NAGOYA UNIVERSITY OF ARTS AND SCIENCES   (Japan)

^b Meijo Hospital   (Japan)

Author keywords

Acute necrotizing; Cholangiopancreatography; Edoscopic retrograde; Gabexate; Nafamostat; Pancreatitis; Protease inhibitors; Urinastatin

Indexed keywords

APROTININ; GABEXATE MESILATE; NAFAMSTAT MESILATE; OCTREOTIDE; PLACEBO; PROTEINASE INHIBITOR; SOMATOSTATIN; TRYPSIN; TRYPSINOGEN; ULINASTATIN;

ACUTE PANCREATITIS; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SHOCK; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANTI-BACTERIAL AGENTS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; INFUSIONS, INTRA-ARTERIAL; ISCHEMIA; JAPAN; PANCREATITIS; PROTEASE INHIBITORS;

EID: 34547930924     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Pandol SJ, Saluja AK, Imrie CW, Banks PA. Acute pancreatitis: bench to the bedside. Gastroenterology 2007; 132:1127-51.
2. Famularo G, Minisola G, De Simone C. Acute pancreatitis. (Correspondence). N Engl J Med 2006; 355:961.
3. Banks PA. Practice guideline in acute pancreatitis. Am J Gastroenterol 1997; 92:377-86.
4. Dervenis C, Johnson CD, Bassi C, Bradley E, Imrie CW, McMahon MJ, Modlin I. Diagnosis, objective assessment of severity, and management of acute pancreatitis. Santorini consensus conference. Int J Pancreatol 1999; 25:195-210.
5. French Consensus Conference on Acute Pancreatitis: Conclusions and Recommendations. Paris, France, 25-26 January 2001. Eur J Gastroenterol Hepatol 2001; 13:S1-S13.
6. Mayumi T, Ura H, Arata S, Kitamura N, Kiriyama I, Shibuya K, et al. Evidence-based clinical practice guidelines for acute pancreatitis: proposals. J Hepatobiliary Pancreat Surg 2002; 9:413-22.
7. Toouli J, Brooke-Smith M, Bassi C, Carr-Locke D, Telford J, Freeny P, et al. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol 2002; 17:S15-S39.
8. Uhl W, Warshaw A, Imrie C, Bassi C, McKay CJ, Lankisch PG, et al. IAP guidelines for the surgical management of acute pancreatitis. Pancreatology 2002; 2:565-73.
9. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand JA, et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32:2524-36.
10. Working Party of the British Society of Gastroenterology, Association of Surgeons of Great Britain and Ireland, Pancreatic Society of Great Britain and Ireland, Association of Upper GI Surgeons of Great Britain and Ireland. UK guidelines for the management of acute pancreatitis. Gut 2005; 54:iii1-9.
11. Pancreatic Disease Group, Chinese Society of Gastroenterology & Chinese Medical Association. Consensus on the diagnosis and treatment of acute pancreatitis. Chin J Dig Dis 2005; 6:47-51.
12. Heinrich S, Schafer M, Rousson V, Clavien PA. Evidence-based treatment of acute pancreatitis: a look at established paradigms. Ann Surg 2006; 243:154-68.
13. Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, De Maio G. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. JOP. J Pancreas (Online) 2003; 4:41-48.
14. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7.
15. Testoni PA. Preventing post-ERCP pancreatitis: Where are we? JOP. J Pancreas (Online) 2003; 4:22-32.
16. Cavallini G, Frulloni L. Antiproteasic agents in the prevention of post-ERCP pancreatitis: rationale for use and clinical results. JOP. J Pancreas (Online) 2003; 4:75-82.
17. Pande H, Thuluvath P. Pharmacological prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Drugs 2003; 63:1799-812.
18. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy. Italian Group. N Engl J Med 1996; 335:919-23.
19. Mariani A. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? JOP. J Pancreas (Online) 2003; 4:68-74.
20. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003; 98:2182-6.
21. Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006; 38:588-95.
22. Seta T, Noguchi Y, Shimada T, Shikata S, Fukui. Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol 2004; 16:1287-93.
23. Messori A, Rampazzo R, Scroccaro G, Olivato R, Bassi C, Falconi M, et al. Effectiveness of gabexate mesilate in acute pancreatitis. A metaanalysis. Dig Dis Sci 1995; 40:734-8.
24. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993; 104:1165-70.
25. Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000; 47:1147-50.
26. Andriulli A, Leandro G, Clemente R, Festa V, Caruso N, Annese V, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the treatment of acute pancreatitis. Aliment Pharmacol Ther 1998; 12:237-45.
27. Berling F, Genell S, Ohlsson K. High-dose intraperitoneal aprotinin treatment of acute severe pancreatitis: a double-blind randomized multi-center trial. J Gastroenterol 1994; 29:479-85.
28. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993; 14:117-24.
29. Otsuki M, Hirota M, Arata S, Koizumi M, Kawa S, Kamisawa T, et al. Consensus of primary care in acute pancreatitis in Japan. World J Gastroenterol 2006; 12:3314-23.
30. Hayakawa T, Miyazaki I, Bannba T, Takeda Y, Kimura T. The guideline on application and dose of the enzyme inhibitor. In: Saitoh Y, ed. The severe acute pancreatitis in Japan - Guide book of diagnosis and treatment. Tokyo: Kokusaitoshoshuppann, 1991: 44-47.
31. Singh VP, Chari ST. Protease inhibitors in acute pancreatitis: lessons from the bench and failed clinical trials. Gastroenterology 2005; 128:2172-4.
32. Whitcomb DC. Acute pancreatitis. (Author reply). N Engl J Med 2006; 355:961.
33. Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3:376-83.
34. Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006; 21:1065-9.
35. Takeda K, Matsuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996; 171:394-8.
36. Kakugawa Y, Takeda K, Sunamura M, Kawaguchi S, Kobari M, Matsuno S. Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis induced by closed duodenal loop obstruction. Nippon Shokakibyo Gakkai Zasshi. Jpn J Gastroenterol 1990;87:1444-50.
37. Takagi K, Isaji S. Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model. Pancreas 2000; 21:279-89.
38. Satoh H, Harada M, Tashiro S, Shiroya T, Imawaka H, Machii K. The effect of continuous arterial infusion of gabexate mesilate (FOY-007) on experimental acute pancreatitis. J Med Invest 2004; 51:186-93.
39. Takeda K, Matsuno S, Ogawa M, Watanabe S, Atomi Y. Continuous regional arterial infusion (CRAI) therapy reduces the mortality rate of acute necrotizing pancreatitis: results of a cooperative survey in Japan. J Hepatobiliary Pancreat Surg 2001; 8:216-20.
40. Takeda K, Mikami Y, Fukuyama S, Egawa S, Sunamura M, Ishibashi T, et al. Pancreatic ischemia associated with vasospasm in the early phase of human acute necrotizing pancreatitis. Pancreas 2005; 30:40-9.
41. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 1992; 30:358-63.
42. Hirota M, Inoue K, Kimura Y, Mizumoto T, Kuwata K, Ohmuraya M, et al. Non-occlusive mesenteric ischemia and its associated intestinal gangrene in acute pancreatitis. Pancreatology 2003; 3:316-22.